Pfizer is shutting down two clinical studies assessing the anti-myostatin monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
News
Janssen bags new EU approval for Darzalex
Janssen’s Darzalex has been approved in Europe for the first-line treatment of patients with multiple myeloma.
AZ’ lupus therapy fails to hit the mark
AstraZeneca’s experimental drug anifrolumab has failed to hit targets in a late stage trial in patients with lupus.
Sanofi’s Cablivi cleared for rare bleeding disorder
Patients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi.
Evox raises £35m for exosome therapeutics
Oxford, UK-based Evox Therapeutics has raised £35 million to help advance its exosome-based therapeutics pipeline.
FDA rejects Sunovion’s ADHD drug
Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators.
Bayer wins US nod for Jivi
US regulators have approved Bayer’s Jivi (formerly BAY94-9027), a longer-acting Factor VIII therapy designed to reduce the number of infusions necessary to prevent bleeds in patients with Haemophilia A.
Severe asthma patients to get ‘life-changing’ procedure on NHS
A novel treatment for patients with asthma uncontrolled by medicines that involves reducing muscle mass in the lungs has been approved for routine use on the NHS.
US approves MSD HIV drugs Delstrigo and Pifeltro
MSD’s HIV medicines Delstrigo and Pifeltro have been cleared by the US Food and Drug Administration for adult patients with no prior antiretroviral treatment experience.
Alnylam’s RNA therapy Onpattro bags EU nod
Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy.
Shire completes sale of oncology franchise to Servier
Shire has completed the sale of its oncology franchise to Servier in a deal valued at $2.4 billion.
EU approves AZ’ Bydureon BCise device
AstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon.
Vertex invests in Genomics plc as the firms sign research deal
UK analytics group Genomics plc has signed a three-year deal with Vertex centred on improving the discovery of targets for precision medicine, and has also raised £25 million to further expand its business.
EU expands use of Amgen’s Blincyto
European regulators have expanded the scope of Amgen’s Blincyto to include the treatment of younger patients with a rare type of leukaemia.
GSK’s Nucala approved for younger asthma patients
GlaxoSmithKline’s Nucala has been approved for use in paediatric patients with severe eosinophilic asthma.
